Matinas Biopharma Holdings, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
AMEX
Matinas BioPharma's Q2 2026 report reveals severe financial distress, with substantial doubt about its going concern status, despite announcing significant strategic transactions including a business combination and asset sale.
AMEX
Matinas BioPharma reports Q1 2026 net loss of $1.9 million and warns of substantial doubt regarding its ability to continue as a going concern.
AMEX
Matinas BioPharma Holdings, Inc. reported a net loss of $1.532 million for Q3 2025 and $8.433 million for the nine months ended September 30, 2025, with substantial doubt about its ability to continue as a going concern.
AMEX
Matinas BioPharma Holdings, Inc. reported reduced net losses and operating expenses for Q2 2025, but disclosed substantial doubt about its ability to continue as a going concern.
AMEX
10-Q: Matinas BioPharma Reports Q1 2025 Results, Focuses on Strategic Partnerships and Cost Management
Matinas BioPharma reports a net loss for Q1 2025 and is actively seeking strategic partnerships to monetize its assets and manage its cash resources.
AMEX
Matinas BioPharma has ceased all product development and reduced its workforce by 80% following the termination of negotiations for its lead drug candidate, MAT2203.
AMEX
10-Q: Matinas BioPharma Reports Second Quarter 2024 Financial Results Amidst Going Concern Uncertainty
Matinas BioPharma reported a net loss of $11.5 million for the first half of 2024 and faces substantial doubt about its ability to continue as a going concern.
AMEX
Matinas BioPharma reports a net loss of $5.824 million for the first quarter of 2024 and expresses substantial doubt about its ability to continue as a going concern.